Our Voice Blog

Future Directions in the HER2-Targeted Treatment of Lung Cancer

Suresh S. Ramalingam, MD Category: Oncology Education

Safety of HER2-Targeted ADCs in NSCLC

Jennifer W. Carlisle, MD    Category: Oncology Education

Efficacy of HER2-Targeted ADCs in NSCLC

Jennifer W. Carlisle, MD    Category: Oncology Education

What to Target: HER2 Mutations, Amplifications, and/or Overexpression?

Jennifer W. Carlisle, MD    Category: Oncology Education

Why Target HER2 in NSCLC?

Suresh S. Ramalingam, MD  Category: Oncology Education

CME is Effective! Now What?

Jason Olivieri, Director, Outcomes, Med-IQ Category: Outcomes

Med-IQ Minute: Case of the Week #16 – Angry Patients 2 of 2

Caty House, Director of Education, Med-IQ Category: Med-IQ Minute

P Values – Controlling for Multiple Comparisons

Jason Olivieri, Director, Outcomes, Med-IQ Category: Outcomes

Med-IQ Minute: Case of the Week #15 – Angry Patients 1 of 2

Caty House, Director of Education, Med-IQ Category: Med-IQ Minute

Next >